Industry / Switzerland
Roche To Reduce Tarceva Price To Gain NICE Approval
July 2008 | Industry NewsFollowing a negative appraisal from the UK's National Institute for Health and Clinical Excellence (NICE), Roche is to lower the price of its non-small cell lung cancer treatment Tarceva (erlotinib). The drug was not found to be cost effective by the advisory body when compared with another already used treatment, Sanofi-Aventis' Taxotere
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
